-
Deliveroo keeps on growing – but when will it turn a profit?
Analysis Deliveroo is still growing its sales and competing with rivals Uber Eats and Just Eat for market share. But will it ever make a profit? Rupert Hargreaves reports.
Analysis -
Why ABF's share price is cheap and attractive right now
Analysis This one-time FTSE 100 favourite has been through some tough times, but the future is looking much brighter and the shares are cheap, says David J Stevenson.
Analysis -
You may not like tobacco stocks, but they treat their investors very well
Analysis The tobacco sector may not be ESG-friendly, but it has produced outstanding returns for investors in the past. Rupert Hargreaves looks at whether this can continue – and picks the stock with the best prospects.
Analysis -
Homebuilders look cheap, but this is a better bet on the UK housing market
Tips If you’re looking to get exposure to the UK housing market, don’t buy the builders – buy this stock instead.
Tips -
Lockdown winner Homeserve has had another strong year
News HomeServe's stock price has shot up since Brookfield Asset Management said one of its private infrastructure funds is putting a bid for the home repair company. Rupert Hargreaves explains what is going on.
News -
The FTSE 100 is doing moderately well – can this continue?
Analysis The FTSE 100 performed well and better than expected in the first quarter of 2022. John Stepek looks at what has changed.
Analysis -
UK stocks should cope with rising interest rates better than other markets
Analysis Central banks are turning hawkish and raising interest rates. John Stepek looks at what that means for both long duration and short duration assets.
Analysis -
Why GSK should turn down Unilever’s billions
News Unilever has offered GSK £50bn for its consumer division. But while the cash will be a temptation, the deal is not in the interests of shareholders or of anyone else, says Matthew Lynn.
News -
Unilever slides and GSK bounces after GSK knocks back £50bn bid
News Unilever shares fell to their lowest level in around five years, after its £50bn takeover bid for GSK’s consumer health unit was rejected.
News
